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Abstract While postnatal toxoplasmosis in immune-
competent patients is generally considered a self-limiting
and mild illness, it has been associated with a variety of more
severe clinical manifestations. The causal relation with some
manifestations, e.g. myocarditis, has been microbiologically
proven, but this is not unequivocally so for other reported
associations, such as with epilepsy. We aimed to systematical-
ly assess causality between postnatal toxoplasmosis and epi-
lepsy in immune-competent patients. A literature search was
performed. The Bradford Hill criteria for causality were used
to score selected articles for each component of causality.
Using an arbitrary but defined scoring system, the maximal
score was 15 points (13 for case reports). Of 704 articles, five
case reports or series and five case–control studies were se-
lected. The strongest evidence for a causal relation was pro-
vided by two case reports and one case–control study, with a
maximal causality score of, respectively, 9/13, 10/13 and 10/
15. The remaining studies had a median causality score of 7
(range 5–9). No selection bias was identified, but 6/10 studies
contained potential confounders (it was unsure whether the
infection was pre- or postnatal acquired, or immunodeficiency
was not specifically excluded). Based on the evaluation of the
available literature, although scanty and of limited quality, a
causal relationship between postnatal toxoplasmosis and
epilepsy seems possible. More definite proof requires further
research, e.g. by performing Toxoplasma serology in all de
novo epilepsy cases.
Introduction
Toxoplasmosis is caused by the intracellular parasite
Toxoplasma gondii, which has felines as the definitive host
and a variety of vertebrates as intermediate hosts. The clinical
manifestations in humans depend on whether it is transmitted
pre- or postnatally, on gestational age in case of prenatal trans-
mission and on host immune status. A recent publication
based on registered diagnoses from private insurance records
reported significant morbidity and mortality related to toxo-
plasmosis, underscoring the relevance of the subject [1].
The seroprevalence of toxoplasmosis, as reflected by the
presence of IgG antibodies against T. gondii, differs world-
wide. In the USA, the seroprevalence was approximately
14% by the age of 40 years old [2], while in the
Netherlands, the seroprevalence was 47% in the age category
40–44 years of age [3]. In postnatal infected immune-
competent individuals, the clinical course is asymptomatic in
90% of the cases, while in the remaining 10%, it usually
presents as lymphadenopathy, in which especially the cervical
nodes are involved [4]. Lymphadenopathy can be accom-
panied by fever, rash, sore throat, hepatosplenomegaly and
atypical lymphocytosis. Myocarditis, hepatitis, pneumoni-
tis, polymyositis and encephalitis have been reported but
are rare manifestations [4].
During the past several years, seropositivity for T. gondii
has been associated with various diseases, including e.g. ma-
lignancies (e.g. breast cancer, melanoma or non-Hodgkin lym-
phoma) and auto-inflammatory diseases (systemic lupus ery-
thematosus, rheumatoid arthritis or granulomatosis and
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polyangiitis) [5]. However, the association was neither sup-
ported by a solid hypothesis on the pathogenesis nor by evi-
dence of causality and the actual role of T. gondii in these
diseases therefore remains speculative. An association with
neurological manifestations such as Alzheimer’s disease,
Bell’s palsy, migraine and epilepsy has also been reported
[5], which would be more plausible given the neurotropic
nature of T. gondii. In a recently published meta-analysis by
Ngoungou and colleagues, which included studies of
immune-competent patients with toxoplasmosis as well as of
patients with congenital toxoplasmosis or with human immu-
nodeficiency virus (HIV) infection, it was concluded that toxo-
plasmosis should be regarded as a risk factor for epilepsy [6].
While the risk of epilepsy in congenital toxoplasmosis or in
a setting of impaired immunity is unequivocal, this is not the
case for postnatal toxoplasmosis in immune-competent indi-
viduals. In the present study we, therefore, specifically aimed
to evaluate the possible causal role of postnatal toxoplasmosis




A literature search was performed on February 5th 2015 of the
PubMed, Medline, Embase, Web of Science and Cochrane
databases. The keywords were ‘toxoplasmosis’ and ‘epilep-
sy’; for the full search, see the supplementary material. An
additional search was conducted on July 14th 2016 using
Medline and the keywords were ‘toxoplasm* epilepsy 2015
2016’.
Selection of studies
Articles were selected based on the title and, when potentially
relevant, the abstract. Included were studies on toxoplasmosis
and epilepsy published between 1966 and July 2016.
Exclusion criteria were toxoplasmosis in patients with HIV
infection or any other primary or secondary immune deficien-
cy, congenital toxoplasmosis, publications in any language
other than English, French or Dutch and animal studies.
Scoring of causality (Bradford Hill)
In order to construct a semi-quantitative measure for causality
in each article, the nine criteria for causality were used as
published by Sir Austin Bradford Hill in 1965 [7]. These
criteria consisted of strength, consistency, specificity, tempo-
rality, biological gradient, plausibility, coherence, experiment
and analogy, as shown in Table 1, which shows the arbitrary
scoring system that was specifically developed for this study.
Scores for each article were given by both authors and in case
of discrepancy, consensus was obtained. The maximal achiev-
able score was 15 (for case reports, this was 13, as the criterion
of strength was not applicable).
Scoring for bias and confounding
Articles were quali tat ively assessed on potential
bias/confounding (comprised of information bias, selection
bias and confounding).
Citation index and citations
Articles were assessed with regard to scientific impact, using
the impact factor at the time of publication and citation score
at the time of the present study, as reported on the Web of
Science.
Results
The search performed in February 2015 resulted in 701 arti-
cles, of which nine fulfilled the selection criteria. 215 articles
were excluded due an immune deficiency in the patients, 248
articles because it was primarily about a different subject, 63
were about congenital toxoplasmosis, 61 because of the lan-
guage, 32 were animal studies, 72 were not accessible, while
one was a meta-analysis of earlier studies [8]. The nine re-
maining articles consisted of three case reports, one case series
and five case–control studies, with a publication year between
1966 and 2014 [9–17]. The additional search in July 2016
resulted in seven articles, of which three were selected based
on their title and abstract. One of these three were excluded
due to the presence of HIV infection and one was excluded
due to low quality; only the remaining case report was includ-
ed in this study [18], resulting in a total of ten included articles.
The causality scores of the ten included studies are shown in
Table 2. The total score per article ranged from 5 to 10, with
two articles being allocated ten points [9, 17].
Four criteria were not applicable to individual articles but
were scored simultaneously for all articles. For plausibility
and analogy, all ten publications were allocated one point, as
T. gondii is known to infect the brain and the development of
epilepsy is, therefore, biologically plausible, while other par-
asitic infections (e.g. neurocysticercosis caused by Taenia
solium) can cause epilepsy as well [19]. Along the same line,
each article was allocated one point for coherence because the
data didn’t seriously conflict with current knowledge.
Regarding consistency, the studies comprised of various set-
tings and different patient groups. Therefore, each study was
allocated two points. Thus, all ten studies received the maxi-
mal score for these four characteristics; therefore, the minimal
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score was five points and the maximal score 15 (13 for case
reports).
The strength of association was not applicable in the
case reports or series. Of the five case–control studies,
two reported a significant association between seropositivity
for toxoplasmosis and epilepsy [15, 17], while it was not
significant in the other three [12, 14, 16]. Yazar et al. found
a significantly higher seropositivity rate in patients with
cryptogenic epilepsy compared to patients with epilepsy
due to a known cause or to healthy volunteers (p < 0.01)
[15]. Kamuyu et al. performed a large case–control study in
Africa and demonstrated a higher seropositivity rate for
T. gondii in patients with epilepsy compared with age-
matched community controls [odds ratio (OR) = 1.36;
p < 0.015] [17]. Akyol et al. found no significant difference
in seropositivity for T. gondii in 100 patients with epilepsy
compared to 50 healthy controls [16]. Critchley et al. did
not report statistical data but concluded that the prevalence
of T. gondii antibodies in 204 patients with epilepsy was
not in excess of that found in a non-epileptic population
from another study [12]. Stommel et al. showed, after ad-
justment for age and gender, no difference in seropositivity
between 22 patients with cryptogenic epilepsy and 23
healthy controls, but did report a higher antibody titre for
T. gondii in patients with epilepsy compared with non-
epileptic controls (Wilcoxon rank-sum test, p = 0.013) [14].
Table 1 Criteria and scoring method for assessment of the causality of postnatal toxoplasmosis for the development of epilepsy
Bradford Hill
criteria
Explanation Score (points) Criteria for score
Strength What was the strength of the association? OR/RR is strong
(2)
2: OR/RR ≥ 4 and significant
OR/RR is weak
(1)
1: OR/RR< 4 and significant
No association
(0)




Consistency Was the result found in different settings, by different authors?a Yes (2) 2: if ≥ 2 different settings and ≥ 2 different groups
Yes (1) 1: if ≥ 2 different settings or ≥ 2 different groups
No (0) 0: only 1 setting and 1 group
Specificity Was the tested group representative for a general conclusion? Yes (2) 2: tested group reflects population of interest
Partially (1) 1: tested group was randomly selected from a
subgroup
of the population of interest
No (0) 0: strongly selected subjects
Temporality Did the effect take place after the exposure? Yes (2) Note that exposure indicates infection with
T. gondiiNo or not
evaluable (0)
Gradient Is there a relation between the amount of exposure and (the
severity of) the disease?
Yes (2) For lack of alternative parameter, amount of
exposure
was defined as higher antibody titres to
T. gondii
No (0)
Plausibility Is the causation biologically plausible?a Yes (1) 1: a plausible pathophysiological explanation is
availableNo (0)
Coherence Is the relation between exposure and disease in
conflict with our current data?a
No (1) Current data consist of knowledge taught in
standard medical




Experiment Did anti-Toxoplasma treatment improve the
alleged associated disease?
Yes (2) 2: treatment was randomised
Yes (1) 1: treatment was not randomised
No/not sure (0)
Analogy Are there similar associations?a Yes (1) 1: any other infection associated with
development of epilepsyNo (0)
a These four criteria were not applicable to individual articles but were scored simultaneously for all articles in the present study (see the Results section)
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A gradient, here defined as higher T. gondii antibody titres
among a group of patients with epilepsy, was found in one
case–control study, in which high antibody titres were more
strongly associated with epilepsy (OR = 1.36; p < 0.015) than
lower antibody titres (OR = 1.25; p < 0.069) [17].
The case–control studies were more or less representative
for a general conclusion (specificity), while single case reports
were allocated one point.
Regarding temporality, only three case reports and
the case series demonstrated unequivocally that the ep-
ileptic seizures took place after infection with T. gondii
[9, 11, 13, 18].
Regarding the criterion of experiment, four individual pa-
tients had received anti-toxoplasmosis therapy. In four out of
six patients, the epileptic insults resolved [9, 13], while two
others did not recover [10, 18]. Due to lack of controls, the
effect of treatment could not be interpreted with certainty.
Only the case series and case report were allocated one point
for this criterion.
In all, the strongest evidence for a causal relation was pro-
vided by one case report, one case series and one case–control
study, each with a causality score of 9 or 10 points [9, 13, 17].
The remaining studies had a median causality score of 7
(range 5–9).
We found no selection bias, but six out of ten studies
contained potential confounders, as indicated in Table 3 (in
five, it was unsure whether the infection was pre- or postna-
tally acquired; in one study, immunodeficiency was not spe-
cifically excluded). The scientific impact of the selected arti-
cles was limited. The impact factor of the journals in which the
selected studies were published varied from 1.1 to 4.5 and the
number of citations per article varied from 0 to 31.
Discussion
In this study, we performed a systematic assessment of cau-
sality of postnatal toxoplasmosis for the development of epi-
lepsy in immune-competent patients. Worldwide, approxi-
mately 50 million individuals suffer from epilepsy. Among
known causes are, e.g. genetic syndromes, prenatal or perina-
tal brain damage, infections of the brain or brain tumours, but
in 60% of the patients the cause remains unknown [20]. It
would, therefore, be relevant to know whether a common
infection such as postnatal toxoplasmosis can cause epilepsy,
and, if it can, how frequent this occurs.
Previous studies of epilepsy and toxoplasmosis included
cases with congenital as well as with postnatal toxoplasmosis
and, in addition, often included immunocompromised individ-
uals. The recentmeta-analysis byNgoungou and colleagues of
the relationbetween toxoplasmosis and epilepsy,which includ-
ed studies of congenital toxoplasmosis and immunocompro-
misedpatients, foundanestimatedORof2.25[95%confidence
interval (CI) 1.15 to 3.93] [6]. In a large data analysis based on
reported diagnoses from insurance records, a significant asso-
ciation between toxoplasmosis and epilepsy was reported (OR
3.51,95%CI3.00–4.12), thus in the samerangeaswas found in
themeta-analysis, but as a result of the studydesign, it couldnot
be ascertained which proportion concerned patients with con-
genital toxoplasmosis orwith an immune deficiency [1]. It was
acknowledged that directionality and causality of observed re-
lationships between toxoplasmosis and associated comorbidi-
tieswere not clear. The specific focus of our studywas to assess
the causality of postnatal toxoplasmosis for the development of
epilepsy specifically in immune-competent individuals.
Based on a literature search, ten articles were selected, five
of which were case reports or case series and the remainder
were case–control studies. In general, case reports are not used
in formal meta-analyses, but for the particular purpose of this
study, i.e. assessment of causality, the case reports actually
provided the most convincing evidence by fulfilling the crite-
rion for temporality, i.e. certainty that the exposure had oc-
curred before and not after the patient had developed epilepsy.
In all five case–control studies, it could not be excluded that
infection with T. gondii and resulting positive serology had
occurred after the patients had developed epilepsy because
those studies included patients with previously diagnosed ep-
ilepsy and not de novo epilepsy as in the case reports. Even the
presence of IgM antibodies, as was reported in some studies,
does not prove recent infection because IgM may remain de-
tectable for years [21]. Along the same line, because the time
since infection was not known, a potential confounder in the
case–control studies was that some or all of the patients could
have had congenital toxoplasmosis which first manifested as
epilepsy later in life. These limitations of the case–control
studies justify the inclusion of case reports in the present
assessment.
Table 3 Bias and confounding of selected articles
Reference Bias and confounding
Information bias Selection bias Confounding Total
[9] 0 0 0 0
[10] 0 0 1 1a
[11] 0 0 0 0
[12] 0 0 1 1b
[13] 0 0 0 0
[14] 0 0 1 1b
[15] 0 0 1 1b
[16] 0 0 1 1b
[17] 0 0 1 1b
[18] 0 0 0 0
a In this study, immunodeficiency was not specifically excluded
b In these five studies, it was unsure whether the infection was pre- or
postnatally acquired
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Acknowledging temporality as an essential causality factor,
this was most convincingly illustrated in the case report by
Beltrame and colleagues [18]. In summary, this report de-
scribes an immune-competent 15-year-old boy who devel-
oped epileptic insults after having eaten raw meat and vegeta-
bles while on a vacation in Ethiopia. Abnormalities were seen
on the electroencephalogram (EEG) and serology for T. gondii
was positive for both IgM and IgG with low avidity, together
convincingly indicating recent infection. The patient received
anti-toxoplasmosis therapy, after which the EEG pattern was
restored to normal. However, 5 months later, the patient again
had seizures with EEG abnormalities, and anti-epileptic drug
treatment had to be restarted. In our opinion, this case history
convincingly supports a causal relation between toxoplasmo-
sis and epilepsy in an immune-competent person.
The presumed pathogenesis of how T. gondii would cause
epilepsy is not yet fully understood, but if a causal relation actu-
ally exists, then the process is most likely multifactorial, with a
contribution by both the immune response of the host and
parasite-induced altered neurotransmission. The potential mech-
anisms contributing to the pathogenesis have recently been
reviewed in detail by Ngoungou and colleagues [6]. In short, in
the intermediate host, which includes humans, T. gondii forms
cysts in several tissues, including the brain, infecting both neu-
rons and glial cells [6]. A rupture of the cysts leads to an expul-
sion of bradyzoites, followed by a Tcell immune response of the
host, resulting in inflammation and scar tissue, which has been
suggested as one of the main mechanisms leading to epilepsy [8,
18]. A recent study in mice showed that the presence of T. gondii
tissue cysts led to an alteration in the gamma-aminobutyric acid
(GABA) pathway, GABA being an inhibitory neurotransmitter
[22]. This led to seizures in the infected mice and, while still
highly speculative, this mechanism might contribute to the de-
velopment of epilepsy in humans as well. In human patients with
ocular toxoplasmosis, certain genotypes were overrepresented in
immune-competent patients and, although speculative at present,
strain-specific virulence, parasite stage and size or type of inoc-
ulummay contribute to the development of severemanifestations
of toxoplasmosis in immune-competent individuals [23, 24].
Based on the present study, it is not possible to either finally
prove or disprove a causal relation between postnatal toxo-
plasmosis and epilepsy. Because the seroprevalence of
T. gondii is high and the proportion of patients with crypto-
genic epilepsy is considerable, a chance co-occurrence could
not be excluded. Not all of Hill’s criteria of causation have to
be fulfilled to transform an association into belief of causation
and Hill himself stated that our decision to take action is not a
matter of causation but a matter of its merits [7]. Because
epilepsy is a chronic disease that affects many aspects of a
patient’s life and often requires prolonged use of anti-
epileptic drugs, we think further study into a potentially treat-
able cause of epilepsy is justified. Obviously, experimental
studies in humans are not possible for ethical reasons. A
feasible study design could be to perform T. gondii serology,
including IgM and IgG antibodies plus avidity in order to
differentiate between recent and remote infection, in all inci-
dent cases of epilepsy. If available, a biobank of sera of de
novo cases of epilepsy would provide suitable samples for
such a study in a retrospective fashion. Patients with positive
serology indicating recent toxoplasmosis could be included in
a randomised controlled trial, comparing treatment with anti-
toxoplasmosis therapy with placebo (no such study was found
at http://www.clinicaltrials.gov). However, if a causal relation
actually exists, the interval between toxoplasmosis and the
first manifestation of epilepsy may vary and serology
indicating past infection could still be relevant. Additional
case–control studies including incident epilepsy cases and
adequate controls would be useful. In this regard, it could be
interesting to also study cell-mediated immune responses to
Toxoplasma, which, after all, is mainly an intracellular patho-
gen, analogous to e.g. the interferon-gamma release assays as
are presently used for the diagnosis of tuberculosis infection
[25]. The balance between humoral and cellular responses
might reveal a relevant association with neurological manifes-
tations such as epilepsy.
A limitation of our study is the fact that the scoring system
for the assessment of causality was arbitrary, but we think it,
nevertheless, provides an objective, albeit possibly imprecise,
measure of causality. The main limitation was the lack of
high-quality data in the case–control studies because the tem-
poral relation between infection with T. gondii and epilepsy
could not be assessed. Finally, in some of the case reports, an
underlying immune deficiency was not explicitly excluded,
but because most of these reports were published long before
the start of the HIV epidemic, it was unlikely that these pa-
tients were immunocompromised.
In conclusion, based on the available data, we think that
postnatal toxoplasmosis in immune-competent individuals
may cause encephalitis featuring as epilepsy, which can persist
beyond the acute infection. More definitive proof of causality
and an assessment of the frequency of this association require
further study.
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